Cognition Therapeutics (CGTX)
Developing zervimesine for Lewy body dementia psychosis.
$0.9891
vs last close−0.01 (−1.09%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 23.84% | 22.67M shares | |
|---|---|---|---|
| 67 holders · as of Jun 30, 2026 | |||
| Insiders | 6.93% | 6.59M shares | |
| 9 holders · as of Jun 22, 2026 | |||
| Other | 69.23% | 65.83M shares | |
| remainder | |||
95.09M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
67 holders · 22.67M shares · 5 new positions · 28 increased · 10 reduced · 13 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Bios Capital Management, LP | 6.00M | 6.31% | 0 | Aug 14, 2026 |
| Davenport & Co LLC | 4.26M | 4.48% | +1.37M | Jul 13, 2026 |
| Vanguard Capital Management LLC | 3.44M | 3.62% | +437.0K | Aug 13, 2026 |
| BlackRock, Inc. | 1.26M | 1.33% | +293.6K | Aug 7, 2026 |
| Chescapmanager LLC | 997.0K | 1.05% | 0 | Aug 14, 2026 |
| Geode Capital Management, LLC | 910.0K | 0.96% | −10.2K | Aug 12, 2026 |
| Renaissance Technologies LLC | 693.3K | 0.73% | −423.8K | Aug 13, 2026 |
| Hilton Capital Management, LLC | 549.0K | 0.58% | 0 | Aug 4, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Aaron G.L. Fletcherincl. Bios Equity Partners, LP, Bios Equity Partners Iii, LP +19 more | 6.90% | 6.06M | 13D | Sep 23, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Apr 16, 2026 | Anthony Caggianoofficer: Chief Medical Officer | Purchase | 10,000 | $1.11 | 874,906 |
| Apr 16, 2026 | Lisa Ricciardidirector, officer: CEO & President | Purchase | 9,175 | $1.10 | 1,715,851 |
| Apr 16, 2026 | John Brendan Doyleofficer: Chief Financial Officer | Purchase | 10,000 | $1.13 | 627,509 |
House and Senate disclosures
Not reported.